Brief: Unicycive Enters Into Licensing Agreement With Lotus For Renazorb In Korea

Unicycive Therapeutics

02/02/2023 14:38

Feb 2 (Reuters) - Unicycive Therapeutics Inc  UNCY.O :
    * UNICYCIVE ANNOUNCES EXCLUSIVE LICENSE AND DEVELOPMENT
AGREEMENT
WITH LOTUS FOR RENAZORB IN REPUBLIC OF KOREA
    * UNICYCIVE THERAPEUTICS INC - AGREEMENT INCLUDES UPFRONT
PAYMENT,
ROYALTIES, AND MILESTONE PAYMENTS
    * UNICYCIVE THERAPEUTICS INC - LOTUS WILL BE RESPONSIBLE FOR
DEVELOPMENT, REGISTRATION FILING AND APPROVAL OF RENAZORB IN
REPUBLIC OF KOREA
    * UNICYCIVE THERAPEUTICS - UNDER TERMS OF DEAL LOTUS WILL BE
RESPONSIBLE FOR DEVELOPMENT, REGISTRATION FILING, APPROVAL OF
RENAZORB IN REPUBLIC OF KOREA
    * UNICYCIVE THERAPEUTICS INC -  LOTUS WILL HAVE SOLE
RESPONSIBILITY FOR IMPORTATION OF DRUG PRODUCT FROM UNICYCIVE
    * UNICYCIVE THERAPEUTICS INC -  LOTUS WILL HAVE SOLE
RESPONSIBILITY FOR COSTS OF COMMERCIALIZATION OF RENAZORB IN
REPUBLIC OF KOREA
    * UNICYCIVE THERAPEUTICS INC - CO WILL RECEIVE AN UPFRONT
PAYMENT
OF $750,000 AND MAY RECEIVE UP TO $4.45 MILLION IN MILESTONE
PAYMENTS AND TIERED ROYALTIES

Source text for Eikon:  ID:nGNX6lk6QX 
Further company coverage:  UNCY.O 
 ((Reuters.Briefs@thomsonreuters.com;))